Founding Commercial Partner

gfCas12a (CRISPR) Licensing·Remote, US-based·Equity + Uncapped Revenue Share

G+FLAS Life Sciences, Inc.

— a Seoul National University spin-out and owner of the proprietary gfCas12a (mgCas12a) genome-editing platform — is opening a principal-level commercial seat to drive the global out-licensing and partnering of our CRISPR technology across cell & gene therapy, diagnostics and bioproduction.

The upside

This is a principal's seat. You earn equity in the company and an uncapped share of the licensing revenue you generate — we only win when you win . Business expenses are covered at cost.

What you'll be selling — and why it closes

You won't be pushing a science project. You'll be licensing a de-risked, defensible platform :

• Our own CRISPR nuclease — granted patents in the US, Korea & Japan ; a genuine freedom-to-operate advantage over the incumbent Cas9/Cas12a estates.
• Differentiated technology: exonuclease-fused editing for deeper knockout, and a one-pot, 30-minute point-of-care Detector (e.g., antibiotic-resistance screening).
• A Seoul National University spin-out already partnered with Bayer, Kolon and Kolmar — credibility that opens doors.

How you'll work

• Run your own book. Fully remote, independent — no office, no timesheets, no micromanagement.
• Direct line to the founder-CEO (an SNU professor): decisions in days, not quarters.
• Own the pipeline end-to-end: outreach → technical pitch → term sheets → close; represent us at J.P. Morgan, BIO, ASGCT, Advanced Therapies and beyond.

Who thrives here

• A proven closer in cell & gene therapy licensing/BD — ideally with CRISPR / genome-editing deals signed.
• Demonstrated deal-making and fundraising — you have sourced and closed partnerships and licenses.
• Strong network across pharma/biotech, platform companies and investors; US-based , operating globally.
• Entrepreneurial and performance-driven, equity-minded — you'd rather own your upside than draw a fixed base.

Make your case

• Review our gfCas12a Technology & Licensing Brief (attached).
• Send your CV plus a concise BD Plan — how you would turn gfCas12a into revenue (strategy, target segments/accounts, first moves).
• If your plan is sharp, we'll talk. Shortlisted candidates are invited to interview .

A TTACHMENT

gfCas12a (mgCas12a) TECHNOLOGY & LICENSING BRIEF

engineered for next-generation cell & gene therapy

— and rapid molecular diagnostics.

IN ONE LINE

We discovered our OWN CRISPR nuclease from the human gut

microbiome and engineered it into a high-performance,

IP-clean platform — available now for global out-licensing

and co-development in cell & gene therapy, diagnostics,

and bioproduction.

The CRISPR field is dominated by a few foundational nucleases

(SpCas9, AsCas12a, LbCas12a) whose IP is tightly held — creating

freedom-to-operate (FTO) friction and licensing cost for every

new therapeutic. Meanwhile, multiplex and knock-in editing —

the backbone of allogeneic cell therapy — demand a nuclease

that is efficient, precise, and safe across several loci at once.

gfCas12a answers both: a genuinely novel effector that GFLAS

owns outright, built for the editing problems that matter

most in the clinic.

WHAT gfCas12a IS

A novel Cas12a-family nuclease discovered from the human gut

metagenome — only ~37% amino-acid identity to existing Cas12a

enzymes. Distinct enough to stand on its own composition-of-

matter patents, while keeping what makes Cas12a attractive

for therapy:

Origin ....... human gut commensal → low immunogenicity potential

PAM .......... T-rich (5'-TTTV) → targets AT-rich regions Cas9 can’t

Cut geometry . 5' STAGGERED (sticky-end) → precise HDR knock-in, low chromosomal translocation

Specificity .. low off-target, with a dedicated assay program ENGINEERED FOR PERFORMANCE

POTENCY (6xNLS variant)

A codon-optimized variant with six nuclear-localization signals

(plus K169R/D529R) delivers ~2x the indel efficiency of AsCpf1

(and ~4x the original enzyme). Protein yield is ~3.6x higher

than FnCas12a — lowering manufacturing cost of goods.

The 5' staggered cut favors templated knock-in and reduces

chromosomal translocations during multiplex editing — a key

safety concern for allogeneic CAR-T/NK.

CRISPR PLUS — A BUILT-IN EXONUCLEASE EDGE

A 5'→3' exonuclease fused IN-FRAME to the nuclease. Because

gfCas12a leaves a 5' overhang, the fused exonuclease resects

precisely from that overhang — a synergy blunt-cutting editors

cannot match. Result: substantially deeper, more irreversible

knockout AND enhanced Detector sensitivity — a distinct edge

in both therapeutic editing and diagnostics.

INTELLECTUAL PROPERTY (THE MOAT)

Owned or co-owned with Seoul National University:

(composition of matter — novel nuclease)

6xNLS variant ...... KR (high-efficiency variant)

Split crRNA ........ KR (low-cost multiplex guides)

CRISPR PLUS ........ KR (chimeric editing system)

FTO ADVANTAGE: a Korea-origin, independently discovered enzyme

with granted claims in the US, Korea and Japan lets licensee s

build on a DISTINCT IP foundation — reducing dependence on the

incumbent Cas9/Cas12a estates. (FTO is program- and territory-

specific and should be confirmed per program.)

APPLICATIONS & MARKETS

Allogeneic cell therapy — multiplex KO (TRAC, B2M…) +

(e.g., PCSK9 knockout for familial hypercholesterolemia)

Next-gen / senolytic — target-specific KO/KI for engineered

Research models — genome-edited & humanized animal models

Bioproduction — host-cell glyco-engineering for biologics

ONGOING DEVELOPMENT — WE GROW THE PLATFORM AROUND YOUR NEEDS

gfCas12a is a living platform. Beyond the core enzyme, GFLAS

continuously develops enabling capabilities and provides hands-on

technical support so partners reach their goals. Current

development areas — extended and customized per program — include:

CHOE-Seq (in development) — a proprietary in-cell off-target

profiling method built specifically for Cas12a staggered DSBs,

where conventional GUIDE-seq does not apply.

CREXO (in development) — mgCas12a-based targeted knock-in for

precise insertion of large cassettes (e.g., CAR constructs,

immune-cloaking payloads).

CRISPR PLUS — exonuclease-fused editors for deeper knockout

and higher-sensitivity detection (Section 3).

Program-specific engineering — custom guide/PAM optimization,

and tailored assay design.

OUR COMMITMENT: we don’t just license an enzyme — we stand

behind it. As your needs evolve, our scientific team keeps

advancing the toolkit (off-target validation, knock-in,

detection, delivery) to make your program succeed.

POINT-OF-CARE DETECTION (COLLATERAL CLEAVAGE)

gfCas12a is not only an editor. On recognizing its target, it

performs collateral (trans) cleavage of single-stranded DNA

reporters — which we harness into a rapid molecular Detector.

ONE-POT, 30-MINUTE FIELD TEST: combined with isothermal

amplification in a single tube, a gfCas12a Detector confirms the

presence/absence of a specific gene — e.g., an antibiotic-

resistance gene (blaKPC, blaNDM) — directly at the point of care

in under 30 minutes, with a simple fluorescent or lateral-flow

(pregnancy-test-style) readout and NO thermal cycler.

Because the enzyme is GFLAS-owned, the Detector rests on a

differentiated composition-of-matter foundation vs. incumbent

Cas12a diagnostics. Targets: antimicrobial-resistance (AMR)

testing, companion diagnostics. Open to co-development and

THE LICENSING OPPORTUNITY

GFLAS seeks global licensees and co-development partners —

therapeutic developers, platform companies, tool/reagent

providers, CROs and diagnostics firms. Flexible structures:

Research / evaluation license — enzyme + guides for feasibility

Platform / field license — product rights in a defined field,

with milestones and royalties

and off-target validation; partner advances development

Assay licensing — Detector / off-target assay as a service or kit

WHY PARTNERS CHOOSE gfCas12a: own IP (not sub-licensed) ·

engineered for multiplex & knock-in · built-in exonuclease edge ·

one-pot rapid diagnostics · manufacturing-friendly yield · and a

team that invented the enzyme and supports it end-to-end.

G+FLAS Life Sciences, Inc. · Seoul, Republic of Korea

Confidential brief. Figures reflect internal/published data;

preclinical results do not guarantee clinical outcomes. Patent

statements reflect granted/registered status; FTO is program-

and territory-specific.

G+FLAS Life Sciences is an equal-opportunity organization. This is a contract (independent contractor) engagement.

#CRISPR#GeneTherapy#CellTherapy#BusinessDevelopment#Licensing#Biotech#gfCas12a#RemoteJobs